GCN2 and perk kinase inhibitors and methods of use thereof

US11912668B2 · kind B2 · utility

Assignee

• Deciphera Pharmaceuticals, LLC · US

Inventors

• Daniel L. Flynn · Lawrence, US
• Patrick Kearney · San Francisco, US
• Jeffery Zwicker · Waltham, US
• Gada Al-Ani · Waltham, US
• Salim Javed · Waltham, US
• Yu Mi Ahn · Waltham, US
• Kristen Stoltz · Waltham, US
• Bertrand Le Bourdonnec · Coatesville, US

Key dates

• Filing date: Nov 17, 2021
• Grant date: Feb 27, 2024
• Expiry date: Nov 17, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Described herein are compounds, such as compounds represented by Formula I-R: and pharmaceutically acceptable salts, enantiomers, stereoisomers, and tautomers thereof, that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.